Dupilumab is still not available in Ireland

Help people struggling to manage severe eczema to gain access to a potentially life-changing new treatment. Please write to your TD today, ask them to call on the HSE to reimburse dupilumab urgently:

Dupilumab has been available in Northern Ireland and western Europe for over two years
Write to your TD: add your own story and experiences to the draft email below
For more information about dupilumab, download this factsheet

To send e-mails, follow these four simple steps:

Select your constituency from the dropdown menu
Fill in your name and contact details
Edit the e-mail to reflect your views and experiences
Press send!

Choose constituency:

TDs in this constituency:

Evgenii
Evgenii
Evgenii

Your Name

Your E-mail

Your Postal Address

Your name and contact details will automatically appear at the beginning of the email. Your name, postal address and email will appear at the beginning of the email, your name will appear at the bottom

Edit the email to reflect your own point of view and experiences

Dear TD’s Name

I am writing to you about the availability in Ireland of a drug named ‘dupilumab’ which has been life-changing for many people living with severe atopic eczema.

Irish patients are among the very last people in Europe to have access to this treatment, which has been available in Northern Ireland through the NHS for over two years.

Moderate-to-severe eczema can be a life-long condition - with inflamed, dry, and broken skin - which is exhausting to treat, painful, and intensely itchy.  The condition is associated with sleep deprivation and profoundly impacts quality of life by limiting capacity to engage in day-to-day activities, school performance and ability to work.

Dupilumab is the first ever targeted treatment designed specifically for atopic eczema.  Existing treatments for patients are repurposed immunosuppressive drugs with significant toxicity profiles, potential side effects and are poorly tolerated, which restrict their use. For some patients, even these treatments do not work; leaving them with no hope.

This new treatment has been under assessment since November 2018 – people with severe eczema have already been waiting too long.  I am asking you to write to the Minister for Health and the HSE’s leadership team to seek equitable access to dupilumab urgently for Irish eczema patients.

I look forward to hearing from you.

Yours sincerely,

Your name will be automatically added here

Follow access-to-dupilumab advocacy developments

The ISF has been working to raise awareness and to secure access to dupilumab, follow developments below:

Find out more about ISF advocacy click here. If you have questions about dupilumab or this campaign please e-mail us at info@irishskin.ie

You can also monitor the progress on the HSE’s assessment of dupilumab by following this link: http://www.ncpe.ie/drugs/dupilumab-dupixent/

This webpage and campaign is an independent advocacy initiative of the Irish Skin Foundation, it has been not supported or sponsored by Foundation Partners or corporate donations.

For more information about atopic dermatitis and eczema, visit our main eczema page here. If you need help or guidance about managing your eczema, contact the ISF Helpline here.